Clinical Trials Browser

Phase 2 × Myeloproliferative Disorders × monalizumab × Clear all

NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Phase 2 Recruiting

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute